Morgan Stanley
TRVI icon

Morgan Stanley’s Trevi Therapeutics TRVI Stock Holding History

Morgan Stanley’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.72M Sell
731,255
-319,041
-30% -$3.57M ﹤0.01% 3676
2025
Q4 		$13.1M Sell
1,050,296
-3,251,430
-76% -$37.6M ﹤0.01% 3353
2025
Q3 		$39.4M Buy
4,301,726
+3,277,715
+320% +$24.6M ﹤0.01% 2224
2025
Q2 		$5.6M Buy
1,024,011
+529,444
+107% +$3.29M ﹤0.01% 3968
2025
Q1 		$3.11M Buy
494,567
+303,698
+159% +$1.45M ﹤0.01% 4301
2024
Q4 		$786K Sell
190,869
-7,611
-4% -$24.4K ﹤0.01% 5212
2024
Q3 		$663K Buy
198,480
+109,499
+123% +$325K ﹤0.01% 5268
2024
Q2 		$265K Buy
88,981
+20,754
+30% +$57.7K ﹤0.01% 5557
2024
Q1 		$235K Sell
68,227
-229,779
-77% -$513K ﹤0.01% 5677
2023
Q4 		$399K Buy
298,006
+263,292
+758% +$399K ﹤0.01% 5704
2023
Q3 		$75.7K Sell
34,714
-3,077
-8% -$6.95K ﹤0.01% 6001
2023
Q2 		$90.3K Buy
37,791
+37,407
+9,741% +$94.3K ﹤0.01% 5997
2023
Q1 		$710 Sell
384
-55
-13% -$124 ﹤0.01% 7390
2022
Q4 		$848 Sell
439
-427,966
-100% -$844K ﹤0.01% 7488
2022
Q3 		$660K Buy
+428,405
New +$1.4M ﹤0.01% 5120
2022
Q2 		– Sell
-589
Closed -$1K – 7974
2022
Q1 		$1K Buy
+589
New +$610 ﹤0.01% 7873
2021
Q2 		– Sell
-1,000
Closed -$3K – 7804
2021
Q1 		$3K Buy
+1,000
New +$2.93K ﹤0.01% 7222
2019
Q4 		– Sell
-114
Closed -$1K – 6763
2019
Q3 		$1K Sell
114
-5,545
-98% -$30.1K ﹤0.01% 6578
2019
Q2 		$42K Buy
+5,659
New +$48.7K ﹤0.01% 5681

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Morgan Stanley's TRVI Position: Q1 2026 in Review

Morgan Stanley reduced its Trevi Therapeutics (TRVI) stake by 30% in Q1 2026, selling an estimated $3.57M and leaving 731,255 shares worth $8.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

Morgan Stanley first reported a position in TRVI in Q2 2019 and has held it in 19 quarters since. The position peaked at $39.4M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Morgan Stanley held 731,255 shares of Trevi Therapeutics worth $8.72M as of Q1 2026.
  • Morgan Stanley sold 319,041 Trevi Therapeutics shares in Q1 2026, an estimated $3.57M.
  • Trevi Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3676 holding.
  • Morgan Stanley first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 19 quarters since.
  • Morgan Stanley's Trevi Therapeutics position peaked at $39.4M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.